



Custom Isotope Labeling



Pharmacokinetic studies have traditionally used radiolabeled target compounds as a means for evaluating body absorption, distribution, metabolism, and excretion (ADME). Newer analysis technologies have now made it possible to use targets enriched with stable isotopes such as carbon-13 and deuterium as alternatives to radioisotopes.

Whether one is interested in radioisotopes or stable isotopes, only a limited number and variety of isotopically enriched intermediates are readily available. The intermediates commonly used in the synthesis route for your desired target compound may not exist as labeled compounds; thus, a whole new synthesis will be needed for incorporation of the isotope of interest. SRI



can help.

SRI has nearly 50 years of experience in the design and synthesis of complex drugs. SRI's radiochemists understand the requirements of labeling biologically active compounds so that pharmacologists, toxicologists, and biochemists will have the tools needed for producing toxicological and pharmacokinetic data for new pharmaceuticals, chemicals, and pesticides. We can

- Incorporate isotopic labels at specific positions of the compound, including double labeling and multiple site labeling schemes
- Synthesize compounds labeled with stable isotopes for LC/MS studies
- Prepare target compounds by biosynthesis, semisynthesis, or total synthesis
- Handle multi-Curie amounts of ^3H , ^{14}C , ^{32}P , and ^{125}I other radioisotopes necessary for biological studies in our specially designed, environmentally sound, controlled-access facilities
- Work together with pharmacokineticists, biochemical pharmacologists, and mass spectrometrists in conducting ADME/PK and other biochemical studies



Bridging the drug development gap

